Oncolytic virus therapeutics for cancer
| Date | Round | Amount |
|---|---|---|
| Jan 2021 | Series A Oxford biotech Theolytics raised a $6.8M Series A co-led by Epidarex Capital and Taiho Ventures, with Oxford Sciences Innovation. | $6.8M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.